Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Elise A. Olsen(Durham Technical Community College), Eric C. Vonderheid(Ashford and St Peter's Hospitals NHS Foundation Trust), Steven T. Rosen(Unknown), José Antônio Sanches(Universidade de São Paulo), Madeleine Duvic(Cancer Clinic), H. Miles Prince(Peter MacCallum Cancer Centre), Robert Knobler(Medical University of Vienna), Stuart R. Lessin(Fox Chase Cancer Center), Pablo L. Ortiz‐Romero(Hospital Universitario 12 De Octubre), Teresa Estrach(Hospital Clínic de Barcelona), Keiji Iwatsuki(Okayama University), Gary S. Wood(University of Wisconsin–Madison), Michael Girardi(Yale University), Makoto Sugaya(International University of Health and Welfare), M. Bagot(Inserm), Rein Willemze(Leiden University Medical Center), Annamari Ranki(University of Helsinki), Mark R. Pittelkow(Mayo Clinic in Arizona), Lauren Pinter‐Brown(University of California, Irvine), Maarten H. Vermeer(Leiden University Medical Center), Richard T. Hoppe(Stanford Medicine), Lorenzo Cerroni(Medical University of Graz), Joan Guitart(Northwestern Memorial Hospital), Peter Heald(Yale University), Reinhard Dummer(University Hospital of Zurich), Sean Whittaker(Guy's Hospital), Sarah McCue Horwitz(New York University), Larisa J. Geskin(Ashford and St Peter's Hospitals NHS Foundation Trust), Youn H. Kim(Stanford University), Brigette Dréno(Ashford and St Peter's Hospitals NHS Foundation Trust), Marie‐France Demierre(Ashford and St Peter's Hospitals NHS Foundation Trust), Maria Grazia Bernengo(University of Turin), Günter Burg(Center for Pediatric Endocrinology Zurich), Sareeta Parker(Ashford and St Peter's Hospitals NHS Foundation Trust), Nicola Pimpinelli(University of Florence)
Cited by 657
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k